Novartis's Sandoz strikes deal for biosimilar of Herceptin
Novartis's Sandoz division has struck a deal with Taiwan's EirGenix Inc to market a biosimilar version of Roche's Herceptin that is now in late-stage development to treat some cancer tumors. (Source: Reuters: Health)
Source: Reuters: Health - April 30, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Seven-Year Follow-Up Results Can Help HER2+ Breast Cancer Patients Avoid Overtreatment
The combination of trastuzumab and paclitaxel ' represents an important step forward in de-escalating therapy ' for HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 12, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
MyPathway Subanalysis Backs Combination HER2-Targeting Antibodies in Colorectal Cancer
Investigators studied a combination of pertuzumab and trastuzumab in patients with metastatic, HER2-positive colorectal cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 10, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news
AstraZeneca, Daiichi Sankyo partner on cancer ADC
AstraZeneca has entered into an agreement with Daiichi Sankyo to develop and commercialize trastuzumab deruxtecan (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 5, 2019 Category: Pharmaceuticals Source Type: news
On the TRAIL of a Solution to Trastuzumab Resistance in HER2+ Breast Cancer
A genomic and proteomic analysis of HER2+ breast cancer cell lines that are resistant to trastuzumab found a deregulation of the cell death pathway known as TRAIL. (Source: CancerNetwork)
Source: CancerNetwork - April 3, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
AstraZeneca could pay Daiichi Sankyo up to $6.9 billion in cancer drug deal
AstraZeneca Plc and Daiichi Sankyo Co Ltd signed a deal to develop and sell Daiichi's cancer drug trastuzumab deruxtecan that could see the British drugmaker pay as much as $6.9 billion to its Japanese partner. (Source: Reuters: Health)
Source: Reuters: Health - March 29, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Trastuzumab Tied to Higher Long - Term Risk for Heart Failure
Increased risk for heart failure seen in breast cancer survivors given trastuzumab rather than chemo alone (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 21, 2019 Category: Cancer & Oncology Tags: Cardiology, Gynecology, Oncology, Pharmacy, Journal, Source Type: news
Trastuzumab Tied to Higher Long-Term Risk for Heart Failure
WEDNESDAY, March 20, 2019 -- Compared with chemotherapy alone, trastuzumab is associated with a twofold increased long-term risk for heart failure in breast cancer survivors, according to a study published in the March 1 issue of JACC: Heart... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 20, 2019 Category: Pharmaceuticals Source Type: news
Trazimera (Trastuzumab-qyyp) for Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 20, 2019 Category: Drugs & Pharmacology Source Type: news
'Molecular wiring of tumour' predicts breast cancer relapse
New research could lead the way to molecular based treatment and follow-up plans Related items fromOnMedica Thousands of women with breast cancer may be spared chemotherapy Benefit of Herceptin in more breast cancer cases MRI in breast cancer fails to cut reoperation rate Mortality higher if using paroxetine and tamoxifen Physical problems after breast cancer limit survival (Source: OnMedica Latest News)
Source: OnMedica Latest News - March 13, 2019 Category: UK Health Source Type: news
Pfizer ’s Herceptin biosimilar wins FDA nod
Roche ’s blockbuster cancer treatment, Herceptin, will now face increasing competition from a new biosimilar. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 11, 2019 Category: Pharmaceuticals Source Type: news
FDA approves Pfizer's biosimilar to Roche's Herceptin
The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster breast cancer treatment Herceptin. (Source: Reuters: Health)
Source: Reuters: Health - March 11, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
TILs in Patients on Trastuzumab/Pertuzumab-Based Chemo TILs in Patients on Trastuzumab/Pertuzumab-Based Chemo
Evaluation of baseline TIL percentage may provide prognostic information to patients receiving dual HER2 blockade for breast cancer.Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 11, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
FDA Approves Trazimera (trastuzumab-qyyp), a Biosimilar to Herceptin
March 11, 2019 - Pfizer Inc. today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Trazimera (trastuzumab-qyyp), a biosimilar to Herceptin® (trastuzumab),1 for the treatment of human epidermal growth factor... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 11, 2019 Category: Drugs & Pharmacology Source Type: news
T-DM1 Benefits'Striking' in HER2+ Early Breast Cancer T-DM1 Benefits'Striking' in HER2+ Early Breast Cancer
Lidia Schapira provides her perspective on a recent study of trastuzumab emtansine in residual invasive HER2+ breast cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 7, 2019 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news
